Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER study of ianalumab in autoimmune hepatitis
NL-OMON48945Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune hepatitis (AIH) comparing ianalumab with placebo (2 arms). Planned start Oct 2017; status: withdrawn.
02
Drugs
ianalumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NL-OMON48945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48945.